INNOSTAR(688710.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
INNOSTAR
688710.SH
Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally. The company offers screening and discovery, nonclinical assessment stage, and clinical development stage services in the areas of chemical products, biologics, cell and gene therapeutics, radiopharmaceuticals, and traditional Chinese medicines. The company was founded in 2010 and is based in Shanghai, China.
601.49 B
688710.SHMarket value -Rank by Market Cap -/-

Financial Score

01/02/2026 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking15/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.01%D
    • Profit Margin0.02%D
    • Gross Margin46.47%B
  • Growth ScoreE
    • Revenue YoY-26.03%E
    • Net Profit YoY-99.86%E
    • Total Assets YoY-2.73%D
    • Net Assets YoY-0.42%D
  • Cash ScoreC
    • Cash Flow Margin405941.47%A
    • OCF YoY-26.03%E
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreB
    • Gearing Ratio25.17%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Global oncology sector booming to $668B in 2034, with focus on GI tumors. 5 platforms leading the way.

    A recent commentary from Oncolytics Biotech Inc. indicates that the global oncology sector is expected to grow to $668 billion by 2034, driven by a focus on gastrointestinal cancers. The report highlights the importance of research and development in oncology, suggesting a promising future for cancer treatment and the need to address GI tumors in the medical field.

    Unusual Whales·
    US
    ONCY
    -2.90%
    Unusual Whales·
    US
    ONCY
    -2.90%

    Novel TYK2 inhibitor Soficitinib shows promising safety and efficacy in treating moderate-to-severe AD patients, per JAMA Dermatology.

    Soficitinib, a new medication, showed promising results in both safety and effectiveness for individuals with moderate-to-severe atopic dermatitis (AD). The drug exhibited a positive safety profile and encouraging efficacy rates in clinical trials. These findings suggest that Soficitinib could be a beneficial treatment option for patients with AD, offering hope for improved outcomes in this population.

    Unusual Whales·
    SZ
    159837
    -0.99%
    SZ
    159849
    -1.15%
    SH
    512290
    -0.99%
    Unusual Whales·
    SZ
    159837
    -0.99%
    SZ
    159849
    -1.15%
    SH
    512290
    -0.99%

    DUB inhibitors market in 7MM set to expand by 2040 due to novel therapeutics, driven by rising cancer cases.

    The market for DUB inhibitors is expected to experience consistent growth due to increasing focus on targeted protein degradation and innovative oncology treatments. The rising incidence of cancer and neurodegenerative diseases also contributes to the market's expansion. The launch of new products and technologies is anticipated to propel the market further.

    Unusual Whales·
    Unusual Whales·

    17:31 ET DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight

    The DUB inhibitors market is expected to experience significant growth by 2040, driven by the increasing prevalence of cancer and neurodegenerative diseases, along with the launch of novel therapies. Key players like InSilico Medicine and Roche are developing promising DUB inhibitors, with a focus on conditions such as Alzheimer's and Parkinson's diseases. The market is projected to expand due to broad therapeutic applications and improved diagnostics, making DUB inhibitors a vital area for future research and development in oncology and neurology.

    prnewswire·
    prnewswire·

    RET fusion-targeted therapies market to grow significantly by 2034 with the approval of selpercatinib and pralsetinib for RET fusion-positive tumors.

    The market for RET fusion-targeted therapy is poised for significant growth, propelled by increasing recognition of the cancer-causing potential of RET gene fusions and positive results from clinical trials. Approval of targeted drugs like selpercatinib and pralsetinib for RET fusion-positive tumors has further fueled this expansion. The market size is expected to see a notable increase in sales, reaching an estimated value of $X billion in the coming years.

    Unusual Whales·
    Unusual Whales·
    © 2026 Longbridge｜Disclaimer